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Effect of complete epithelial debridement before
riboflavin–ultraviolet-A corneal collagen
crosslinking therapy
Sally Hayes, PhD, David P. O’Brart, MD, Letitia S. Lamdin, James Doutch, BSc,
Kostas Samaras, MD, John Marshall, PhD, Keith M. Meek, PhD
PURPOSE: To evaluate the importance of complete epithelial removal before riboflavin–ultraviolet-A
(UVA) corneal collagen crosslinking therapy.
SETTING: School of Optometry and Vision Sciences, Cardiff University, Wales, United Kingdom.
METHODS: Riboflavin eyedrops were applied at 5-minute intervals for 35 minutes to the anterior
corneal surface of 36 porcine eyes (12 with no epithelial trauma but treated with tetracaine eye-
drops, 12 with superficial epithelial trauma but with an intact basal epithelium, and 12 with a fully
removed epithelium). The corneal surface of 6 tetracaine-treated eyes, 6 eyes with superficial ep-
ithelial trauma, and 6 eyes with a fully removed epithelium was exposed to UVA light for 30 minutes
during riboflavin administration. The light transmission spectra of the enucleated corneas were an-
alyzed with a spectrophotometer and compared with those of 9 untreated porcine corneas.
RESULTS: Corneas with a fully removed epithelium treated with riboflavin showed an abnormal dip
in the transmission spectrum between 400 nm and 510 nm (P<.01). This was attributed to the pres-
ence of riboflavin in the corneal stroma. The spectra of riboflavin-treated corneas with no epithelial
trauma but tetracaine administration and those with superficial epithelial trauma did not differ from
those of the non–riboflavin-treated controls. Exposure to UVA following riboflavin administration
did not alter corneal light transmission.
CONCLUSIONS: Complete removal of the corneal epithelium is an essential component of ribofla-
vin–UVA crosslinking therapy as superficial epithelial trauma and tetracaine administration alone
are not sufficient to permit the penetration of riboflavin into the corneal stroma. Failure to achieve
adequate stromal absorption of riboflavin may impair the efficacy of the crosslinking process.
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Keratoconus is a common noninflammatory, degener-
ative disorder of the cornea, characterized by stromal
thinning and conical ectasia that results in irregular
astigmatism and associated visual loss.1 In most
keratoconic patients, vision can be restored through
the use of hard contact lenses. In cases of advanced
disease, corneal transplantation may be required be-
cause of inadequate contact lens fitting, contact lens
intolerance, or corneal scarring. Keratoconus remains
one of the most common indications for corneal
transplantation.2–5
Riboflavin (vitamin B2)/ultraviolet-A (UVA) (370
nm) corneal collagen crosslinking is a new therapeutic
modality that may be the first treatment available to
stabilize the keratoconic process.6 It is thought to in-
crease the biomechanical stability of the corneal
stroma7,8 and the resistance to enzymatic digestion9
by inducing crosslinkage between the stromal collagen
molecules. The riboflavin has the dual function of act-
ing as a photosensitizer for the production of oxygen-
free radicals, which induce physical crosslinking of
collagen,10 and absorbing the UVA irradiation and
preventing damage to deeper ocular structures such
as the corneal endothelium, the lens, and the ret-
ina.11,12 The technique has been shown to be safe,
with no loss of corneal transparency, no endothelial
damage (provided the cornea is thicker than 400 mm),
and no damage to deeper ocular structures.11,13,14
The riboflavin–UVA corneal collagen crosslinking
method described by Wollensak et al.13 states that
the epithelium should be removed before treatment
to allow penetration of riboflavin into the corneal
stroma. Despite this recommendation, some clinicians
perform the technique with the epithelium intact to
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reduce the patient’s postoperative discomfort.15 They
advocate the use of multiple applications of the topical
anesthetic agent tetracaine 1% before the procedure to
loosen the epithelial tight junctions and allow ribofla-
vin to penetrate the corneal stroma.15 To evaluate the
importance of epithelial removal in facilitating the
entry of riboflavin into the corneal stroma, we mea-
sured the light transmission spectra of porcine corneas
after the administration of riboflavin eyedrops follow-
ing complete epithelial debridement, superficial
epithelial trauma, or no epithelial traumawith the pre-
operative and perioperative administration of topical
tetracaine 1%. These measurements were compared
with those in untreated control corneas and the ab-
sorption spectrum of the riboflavin solution itself.
We also examined the effects of the crosslinking
treatment on light transmission by exposing several
corneas to UVA irradiation in combination with
riboflavin eyedrops.
MATERIALS AND METHODS
Ninety porcine eyes were transported on ice from a local
abattoir within 24 hours of death. Visual examination of
each specimen for the presence of corneal scarring or opacity
resulted in the exclusion of 5 eyes. The remaining 85 eyes
were stored overnight in a sealed bag at 4C. Of these, 45
eyes were selected at random for inclusion in the study
and divided into the following treatment groups:
1. Controls: The corneal epithelium was removed com-
pletely from 5 eyes using a scalpel blade; the epithelium
was left intact in 4 additional corneas.
2. Riboflavin only (superficial epithelial trauma, basal
epithelium intact): Following scraping of the superficial
epithelium for 10 to 15 seconds with a scalpel blade and
visual inspection to ensure the basal layers were intact,
riboflavin drops (10 mg riboflavin-5-phosphate in 10 mL
dextran T-500 20%) were applied to the anterior corneal
surface of 6 eyes at 5-minute intervals for 30 minutes.
3. Riboflavin plus UVA (superficial epithelial trauma, basal
epithelium intact): Following superficial epithelial
trauma, riboflavin drops were applied to the anterior cor-
neal surface of 6 eyes. After 5 minutes, the corneas were
exposed to a 3 mW/cm2 dose of UVA (370 nm) 1 cm
from the anterior surface of the cornea. The crosslinking
treatment lasted 30minutes, during which time riboflavin
drops were applied at 5-minute intervals.
4. Tetracaine plus riboflavin (no epithelial trauma): Topical
tetracaine 1% and riboflavin eyedrops were administered
to the intact, nontraumatized anterior corneal surface of 6
eyes at 5-minute intervals over a 35 minute period to sim-
ulate 5-minute preoperative and 30-minute operative
time periods.
5. Tetracaine and riboflavin plus UVA (no epithelial
trauma): Tetracaine 1% and riboflavin eyedrops were
applied to the anterior corneal surface of 6 eyes with an
intact, nontraumatized epithelium. After 5 minutes, the
corneas were exposed to a 3 mW/cm2 dose of UVA (370
nm) 1 cm from the anterior surface of the cornea. The
crosslinking treatment lasted 30 minutes, during which
time further riboflavin and tetracaine drops were applied
at 5-minute intervals.
6. Riboflavin only (epithelium completely removed): After
a central 10.0 mm area of the corneal epithelium was
completed debrided with a scalpel blade, riboflavin drops
were applied to 6 eyes at 5-minute intervals for 30
minutes.
7. Riboflavin plus UVA (epithelium completely removed):
After the central corneal epithelium was removed
completely, riboflavin drops were applied to the anterior
corneal surface of 6 eyes. After 5 minutes, the corneas
were exposed to a 3 mW/cm2 dose of UVA (370 nm) 1 cm
from the anterior surface of the cornea. The crosslinking
treatment lasted 30minutes, during which time riboflavin
drops were applied at 5-minute intervals.
Immediately after the treatment, each cornea with
a 3.0 mm scleral rim was dissected from the globe and
placed in a specially designed sample holder. The natural
curvature of the cornea was maintained by clamping the
scleral rim in the sample holder and injecting silicone oil
(Dow Corning 200/5cS, BDH Laboratory Supplies) into
the chamber behind it. Silicone oil was also injected into
the front chamber of the holder to maintain a uniform re-
fractive index and reduce light scatter.16 The sample holder
was then positioned into the spectrophotometer (PYE Uni-
cam, SP8-100 UV/VIS) so light passed through the center
of the cornea in the anterior–posterior direction. A trans-
mission spectrum was measured for each cornea at 10
nm intervals in the range of 400 to 700 nm. Using the
method detailed by Kostyuk et al.,16 the transmission spec-
trum for each sample was normalized against a baseline
transmission spectrum of the chamber filled with silicone
oil. A further transmission spectrum over the same wave-
length range (400 to 700 nm) was obtained for the ribofla-
vin solution alone.
RESULTS
Removing the epithelium had no significant affect on
the transmission spectra of the control corneas. In
each case, a gradual increase in light transmission
occurred between 400 and 700 nm. Based on this find-
ing, the spectra of all control corneas (with or without
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epithelia) were averaged for comparison with ribofla-
vin-only and riboflavin-plus-UVA–treated corneas.
Figure 1 shows the mean transmission spectra of con-
trol corneas, corneas treated with riboflavin only, and
corneas treated with riboflavin plus UVA. The stan-
dard error bars associated with each spectrum are
the result of variations in the hydration of corneas
within the treatment groups.
The transmission spectra of corneas with superficial
epithelial trauma (but with the basal epithelium intact)
treated with riboflavin only or with riboflavin and
UVA did not differ from each other or from those of
the control corneas (Figure 1, A). Similarly, the trans-
mission spectra of corneas with no epithelial trauma
treated with riboflavin and tetracaine alone or with
riboflavin, tetracaine, and UVA did not differ from
each other or from that of the control corneas (Figure 1,
B). Complete removal of the epithelium before ribofla-
vin-only or riboflavin-plus-UVA treatment resulted
in a dramatic reduction in light transmission between
400 nm and 510 nm (P!.01) (Figure 1, C). At 450 nm,
light transmission was a mean of 32% lower in
riboflavin-treated corneas that had had complete epi-
thelial removal than in the untreated control corneas.
This dip in light transmission can be attributed to the
presence of riboflavin within the tissue, which absorbs
light between 400 nm and 510 nm (Figure 2). The light
transmission spectra of corneas with a fully removed
epithelium treated with riboflavin plus UVA did not
differ from the spectra of corneas treated with ribofla-
vin alone (Figure 1, C).
DISCUSSION
Riboflavin–UVA corneal collagen crosslinking is the
first therapeutic modality that may halt the progres-
sion of the ectatic process in keratoconus and post-
keratorefractive surgery ectasia.6 Riboflavin is a key
component of the photochemical crosslinking treat-
ment as it increases corneal absorption of UVA to
approximately 95%8 and thereby protects the deeper
ocular structures, especially the endothelium, from
UVA damage.11,12
Thus far, clinical and laboratory studies of corneal
collagen crosslinking have advocated the complete
removal of the epithelium to allow penetration of ribo-
flavin into the corneal stroma.9,12–14,16–18 However, to
reduce the early postoperative discomfort experienced
Figure 1. A: Mean light transmission spectra of 9 untreated porcine
corneas (black triangle), 6 riboflavin-only–treated corneas with su-
perficial epithelial trauma (red triangle), and 6 riboflavin-plus-
UVA–treated corneas with superficial epithelial trauma (green trian-
gle); S.E. bars are shown. B: Mean light transmission spectra of 9 un-
treated porcine corneas (black triangle), 6 riboflavin-and-tetracaine–
treated corneas with an intact epithelium (purple triangle), and 6 ri-
boflavin-and-tetracaine-plus-UVA–treated corneas with an intact
epithelium (yellow triangle); S.E. bars are shown. C: Mean light
transmission spectra of 9 untreated porcine corneas (black triangle),
6 riboflavin-only–treated corneas with epithelium completely re-
moved (pink triangle) and 6 riboflavin-plus-UVA–treated corneas
with epithelium completely removed (blue triangle); S.E. bars are
shown. Figure 2. Light transmission spectrum of riboflavin solution.
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by the patient (as a result of epithelial removal), some
clinicians have performed the procedure with the epi-
thelium intact.15 They postulate that topical anesthetic
drops can loosen epithelial tight junctions, allowing
penetration of riboflavin into the corneal stroma. In
this study, we used spectrophotometry to investigate
the importance of epithelial removal by assessing the
ability of riboflavin to penetrate the stroma of corneas
treated with topical anesthetic eyedrops (tetracaine
1%), of those with superficial epithelial trauma (in
which the basal epithelium remains intact), and of
those with a fully removed epithelium.
We have shown that in the immediate postoperative
period, the light transmission spectra of fully deepithe-
lialized porcine corneas treated with riboflavin eye-
drops are altered by the presence of riboflavin within
the stroma and subsequent exposure of the cornea to
UVA light does not produce further changes in the
transmission spectra. As riboflavin is an essential vita-
min and naturally occurring compound that decom-
poses in the presence of light at wavelengths below
500 nm, the acute changes in light transmission due
to riboflavin absorption will be short-lived; in the clin-
ical setting, the yellow discoloration of the cornea due
to riboflavin, which is clearly visible following the
treatment, is clear 24 hours later (D. O’Brart, personal
observation).13
The normality of the transmission spectra of corneas
that had superficial epithelial trauma but an intact
basal epithelium clearly suggests the need to remove
all epithelial cell layers before treatment to permit
stromal penetration of riboflavin. In our study, the
concomitant use of tetracaine 1%, even if given preop-
eratively and intraoperatively, did not appear to allow
stromal penetration of riboflavin through an intact cor-
neal epithelium. The presence of an intact basal epithe-
lial layer appears to act as an effective barrier to
riboflavin absorption by the corneal stroma, which is
not sufficiently altered by superficial epithelial trauma
or tetracaine eyedrops. Such considerations are very
important as failure to achieve adequate stromal ab-
sorption of riboflavin is likely to severely limit the
crosslinking process.11,14 It is of note, however, that al-
though inadequate stromal absorption of riboflavin
will undoubtedly result in increased UV irradiance
of the endothelium, lens, and retina, at energy levels
of 3 mW/cm2 toxic levels are unlikely to be
reached.11,14,15
Our results do not agree with the clinical results of
Chan et al.15 and Pinelli (R. Pinelli, MD, ‘‘Corneal Col-
lagen Cross-Linking with Riboflavin (C3-R) Treatment
OpensNew Frontiers for Keratoconus and Corneal Ec-
tasia,’’ EyeWorld, May 2007; pages 34–36. Available
at: http://www.eyeworld.org/article.php?sidZ3797.
Accessed January 12, 2008), who performed the
crosslinking procedure with the epithelium intact
and advocated the use of tetracaine 1% to loosen the
epithelial tight junctions. Chan et al. reported a possi-
ble additive effect in reduction in refractive cylinder,
steep and mean keratometry values, and lower–upper
keratometry ratios, with corneal collagen crosslinking
following inferior Intacs insertion compared with infe-
rior Intacs insertion alone in keratoconic eyes. How-
ever, their results must be interpreted relative to the
nonrandomized, retrospective nature of their study
and that keratoconus is a very heterogeneous condi-
tion in which accurate and repeatable refractive, kera-
tometric, and topographic measurements may be
difficult to obtain. In addition, the crosslinking treat-
ment of their patients was performed immediately af-
ter insertion of the intrastromal ring segment and it
may be that epithelial trauma associated with the pro-
cedure (both mechanical and due to exposure) to-
gether with the deep stromal incision required for
ring segment insertion may have facilitated corneal
stromal riboflavin absorption. Pinelli documented
similar outcomes following riboflavin–UVA crosslink-
ing treatment with and without epithelial removal.
Similar to Chan et al., he reported fluorescence in
the anterior chamber, which was attributed to ribofla-
vin penetration, although direct measurements were
not made. While such findings are of interest, we do
not believe they give direct evidence that riboflavin
can be significantly absorbed into the corneal stroma
without removal of all layers of the corneal epithelium
before topical administration and they are not sup-
ported by the spectrophotometric measurements in
this study.
Analysis of the light transmission spectra of porcine
corneas following riboflavin–UVA corneal crosslink-
ing treatment and control corneas suggests the epithe-
lium must be completely removed to allow adequate
penetration of riboflavin into the stroma.
REFERENCES
1. Krachmer JH, Feder RS, Belin MW. Keratoconus and related
noninflammatory corneal thinning disorders. Surv Ophthalmol
1984; 28:293–322
2. Javadi MA, Motlagh BF, Jafarinasab MR, et al. Outcomes of
penetrating keratoplasty in keratoconus. Cornea 2005;
24:941–946
3. Reeves SW, Stinnett S, Adelman RA, Afshari NA. Risk factors
for progression to penetrating keratoplasty in patients with
keratoconus. Am J Ophthalmol 2005; 140:607–611
4. Mamalis N, Anderson CW, Kreisler KR, et al. Changing trends in
the indications for penetrating keratoplasty. Arch Ophthalmol
1992; 110:1409–1411
5. Al-Yousuf N, Mavrikakis I, Mavrikakis E, Daya SM. Penetrating
keratoplasty: indications over a 10 year period. Br J Ophthalmol
2004; 88:998–1001
6. Wollensak G. Crosslinking treatment of progressive keratoco-
nus: new hope. Curr Opin Ophthalmol 2006; 17:356–360
660 LABORATORY SCIENCE: CORNEAL LIGHT TRANSMISSION IN RIBOFLAVIN–UVA CROSSLINKED CORNEAS
J CATARACT REFRACT SURG - VOL 34, APRIL 2008
7. Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of
human and porcine cornea after riboflavin/ultraviolet-A-induced
crosslinking. J Cataract Refract Surg 2003; 29:1780–1785
8. Spo¨rl E, Schreiber J, Hellmund K, et al. Untersuchungen zur
Verfestigung der Hornhaut am Kaninchen. [Cross-linking effects
in the cornea of rabbits]. Ophthalmologe 2000; 97:203–206
9. Spoerl E, Wollensak G, Seiler T. Increased resistance of cross-
linked cornea against enzymatic digestion. Curr Eye Res 2004;
29:35–40
10. Andley U. Photooxidative stress. In: Albert DM, Jakobiec FA,
eds, Principles and Practice of Ophthalmology. Philadelphia,
PA, Saunders, 1994; 575–590
11. Wollensak G, Spoerl E, Wilsch M, Seiler T. Endothelial cell
damage after riboflavin-ultraviolet-A treatment in the rabbit.
J Cataract Refract Surg 2003; 29:1786–1790
12. Spoerl E,WollensakG, Dittert D-D, Seiler T. Thermomechanical
behaviour of collagen cross-linked porcine cornea. Ophthalmo-
logica 2004; 218:136–140
13. Wollensak G, Spo¨rl E, Seiler T. Riboflavin/ultraviolet-A-induced
collagen crosslinking for the treatment of keratoconus. Am
J Ophthalmol 2003; 135:620–627
14. Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin
cross-linking of the cornea. Cornea 2007; 26:385–389
15. Chan CCK, Sharma M, Boxer Wachler BS. Effect of inferior-
segment Intacs with and without C3-R on keratoconus.
J Cataract Refract Surg 2007; 33:75–80
16. Kostyuk O, Navolina O, Mubard TM, et al. Transparency of the
bovine corneal stroma at physiological hydration and its
dependence on concentration of ambient ion. J Physiol 2002;
543:633–642. Available at: http://jp.physoc.org/cgi/reprint/543/
2/633. Accessed January 12, 2008
17. Wollensak G, Wilsch M, Spoerl E, Seiler T. Collagen fiber
diameter in the rabbit cornea after collagen-crosslinking by
riboflavin/UVA. Cornea 2004; 23:503–507
18. KohlhassM, Spoerl E, Schilde T. Biomechanical evidence of the
distribution of cross-links in corneas treated with riboflavin and
ultraviolet A light. J Cataract Refract Surg 2006; 32:279–283
First author:
Sally Hayes, PhD
School of Optometry and Vision Sciences,
Cardiff University, Cardiff, United
Kingdom
661LABORATORY SCIENCE: CORNEAL LIGHT TRANSMISSION IN RIBOFLAVIN–UVA CROSSLINKED CORNEAS
J CATARACT REFRACT SURG - VOL 34, APRIL 2008
